Heavy, small molecule cutting-edge Tongkang Pharmaceutical completed nearly 400 million yuan in B+ round of financing

Recently, Zhejiang Tongyongkang Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Yongkang Pharmaceutical") announced the completion of a B+ round of financing of nearly 400 million yuan.
This round of financing was led by Guohai Innovation Capital, Haibang Fenghua and Zheshang Venture Capital Together with the investment, the old shareholders Wenzhou Investment and Changxing Financial Holdings continued to make additional investments.

Recently, Zhejiang Tongyongkang Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Yongkang Pharmaceutical") announced the completion of a B+ round of financing of nearly 400 million yuan.
This round of financing was led by Guohai Innovation Capital, Haibang Fenghua and Zheshang Venture Capital Together with the investment, the old shareholders Wenzhou Investment and Changxing Financial Holdings continued to make additional investments.

This round of financing will be used for the 2/3 phase clinical advancement of the company's two 1.
1-type new drug projects, the preclinical application and clinical trials of multiple international leading small molecule innovative drug projects, and the construction of innovative drug GMP preparation plants.

This round of financing will be used for the 2/3 phase clinical advancement of the company's two 1.
1-type new drug projects, the preclinical application and clinical trials of multiple international leading small molecule innovative drug projects, and the construction of innovative drug GMP preparation plants.

Focus on the research and development of innovative anti-tumor drugs, based in China, and global deployment

Focus on the research and development of innovative anti-tumor drugs, based in China, and global deployment

Established in November 2017, TongYongkang Pharmaceutical is an innovative biomedical high-tech company based in China and facing the world.
It has a world-class new drug R&D center.
It has established a 6,000 square meter new drug R&D center in Zhejiang Changxing Life Science Park.
New drug research and development centers have been established in Zhengzhou and Shanghai, and the clinical medicine department and business development department have been established in Shanghai.

Established in November 2017, TongYongkang Pharmaceutical is an innovative biomedical high-tech company based in China and facing the world.
It has a world-class new drug R&D center.
It has established a 6,000 square meter new drug R&D center in Zhejiang Changxing Life Science Park.
New drug research and development centers have been established in Zhengzhou and Shanghai, and the clinical medicine department and business development department have been established in Shanghai.

The company focuses on the research and development of anti-tumor small molecule Best-in-class/First-in-class new drugs, and has established a high-efficiency small molecule new drug research and development platform.

Homolog Pharma has a world-class R&D and management team, including 1 national expert, 2 Zhejiang province experts, and more than 10 overseas returnee doctoral experts.
It has rich experience in new drug research and development of well-known multinational pharmaceutical companies and has led more than a dozen compounds into the clinical stage .

Dr.

Dr.

Mr.

Ms.

Mr.

Mr.

About Guohai Innovation Capital

China Sea Innovation Capital Investment Management Co.

China Sea Innovation Capital Investment Management Co.

About Haibang Fenghua

Haibang Fenghua was initiated and established by Zhejiang Haibang Investment, a well-known equity investment institution in Zhejiang Province, and the entire investment management team.

Haibang Fenghua was initiated and established by Zhejiang Haibang Investment, a well-known equity investment institution in Zhejiang Province, and the entire investment management team.

About Zheshang Venture Capital

Hangzhou Qizhen Future Innovation Fund was personally initiated by Academician Wu Zhaohui, President of Zhejiang University, and initiated and established by Zhejiang Business Venture Capital.

Hangzhou Qizhen Future Innovation Fund was personally initiated by Academician Wu Zhaohui, President of Zhejiang University, and initiated and established by Zhejiang Business Venture Capital.

About Wenzhou Investment

Wenzhou Investment is a professional investment company focusing on the domestic and foreign biomedical fields.

Wenzhou Investment is a professional investment company focusing on the domestic and foreign biomedical fields.

About Changxing Financial Holdings

Zhejiang Changxing Financial Holding Group Co.
, Ltd.
is a wholly state-owned enterprise established by the Changxing County Party Committee and Government.
The group implements enterprise management and market operation.
The main business is to operate and manage financial services such as fund investment, equity investment, financial leasing, factoring, and private equity management in accordance with professional and market-oriented rules, and promote the healthy and orderly development of strategic emerging industries in the region.
The company adheres to the corporate philosophy of "integrity, stability, development, innovation, dedication, and professionalism", with a stable investment >

Zhejiang Changxing Financial Holding Group Co.
, Ltd.
is a wholly state-owned enterprise established by the Changxing County Party Committee and Government.
The group implements enterprise management and market operation.
The main business is to operate and manage financial services such as fund investment, equity investment, financial leasing, factoring, and private equity management in accordance with professional and market-oriented rules, and promote the healthy and orderly development of strategic emerging industries in the region.
The company adheres to the corporate philosophy of "integrity, stability, development, innovation, dedication, and professionalism", with a stable investment >